Document Detail


An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors.
MedLine Citation:
PMID:  23652044     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Gambogic acid is a pure active compound isolated from the traditional Chinese medicinal plant gamboge (Garcinia morella Desv.). Based on the preliminary results of a phase I study, this phase IIa study compared the efficacy and safety of different dosage schedules of gambogic acid in patients with advanced malignant tumors.
METHODS: Patients with advanced or metastases cancer who had not received any effective routine conventional treatment or who had failed to respond to the existing conventional treatment were randomly assigned to receive either 45 mg/m(2) gambogic acid intravenously from Days 1 to 5 of a 2-week cycle (Group A), or 45 mg/m(2) every other day for a total of five times during a 2-week cycle (Group B). The primary endpoint was objective response rate (ORR).
RESULTS: Twenty-one patients assigned to Group A and 26 to Group B were included in the final analysis. The ORRs were 14.3% in Group A and 0% in Group B. It was not possible to analyze the significant difference because one of the values was zero. The disease control rates (DCRs) were 76.2% in Group A and 61.5% in Group B (P = 0.0456). The observed adverse reactions were mostly Grades I and II, and occurred in most patients after administration of the trial drug. There was no significant difference in the incidence of adverse reactions between the two arms.
CONCLUSIONS: The preliminary results of this phase IIa exploratory study suggest that gambogic acid has a favorable safety profile when administered at 45 mg/m(2). The DCR was greater in patients receiving gambogic acid on Days 1 - 5 of a 2-week cycle, but the incidence of adverse reactions was similar irrespective of the administration schedule.
Authors:
Yihebali Chi; Xiao-Kai Zhan; Hao Yu; Guang-Ru Xie; Zhen-Zhong Wang; Wei Xiao; Yong-Gang Wang; Fu-Xing Xiong; Jun-Feng Hu; Lin Yang; Cheng-Xu Cui; Jin-Wan Wang
Related Documents :
1440204 - Multimodality treatment of deep periventricular cerebral arteriovenous malformations.
18192104 - Conjunctival hemorrhagic events associated with imatinib mesylate.
16615044 - Moyamoya syndrome following childhood acute lymphoblastic leukemia.
24534684 - Segmental stability in orthognathic surgery: hydroxyapatite/poly-l-lactide osteoconduct...
9752804 - Sclerotherapy with ok-432 for recurrent cystic thyroid nodule.
15347334 - Epidermal naevi treated with pulsed erbium:yag laser.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Chinese medical journal     Volume:  126     ISSN:  0366-6999     ISO Abbreviation:  Chin. Med. J.     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-05-08     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7513795     Medline TA:  Chin Med J (Engl)     Country:  China    
Other Details:
Languages:  eng     Pagination:  1642-6     Citation Subset:  IM    
Affiliation:
Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing 100021, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Perioperative aortic dissection rupture after endovascular stent graft placement for treatment of ty...
Next Document:  Effects of triterpenic acid from Prunella vulgaris L. on glycemia and pancreas in rat model of strep...